Kiran Ubhayakar, MD
Critical Care Medicine · Calistoga, CANPI 1881838605
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (45.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 72.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $11,637 and has fallen 51.3% since, to $5,664 in 2025. Among critical care medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 273 payments — averaging $87.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$17K
- Boehringer Ingelheim$2K
- Actelion Pharmaceuticals US, Inc.$933
- GSK$904
- AstraZeneca$632
- United Therapeutics Corporation$492
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$2,0008%
- Travel & lodging$3,97417%
- Food & beverage$7,09030%
- Education$10,69245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 31 | $17,157 |
| Boehringer Ingelheim | 74 | $1,880 |
| Actelion Pharmaceuticals US, Inc. | 24 | $933 |
| GSK | 49 | $904 |
| AstraZeneca | 25 | $632 |
| United Therapeutics Corporation | 17 | $492 |
| Johnson & Johnson | 5 | $304 |
| Sanofi | 7 | $210 |
| Inari Medical, Inc. | 1 | $185 |
| Bayer | 3 | $106 |
| Verona Pharma, Inc. | 4 | $105 |
| Mayne Pharma Commercial LLC | 4 | $104 |
| Insmed, Inc. | 3 | $77 |
| Medtronic | 1 | $73 |
| Baxter Healthcare | 3 | $68 |
| Electromed, Inc. | 4 | $66 |
| Novo Nordisk | 3 | $62 |
| Merck | 2 | $55 |
| Genentech, Inc. | 1 | $50 |
| ERBE USA Inc | 1 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Advanced Respiratory, Inc | 1 | $20 |
| Novartis | 1 | $18 |
| AbbVie | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$13,717
- ION$3,000
- UPTRAVI$269
- OPSUMIT$269
- FLOWTRIEVER CATHETER, S$185
- CT THROMBECTOMY SYSTEM KIT$185
- AIRSUPRA$125
- OFEV$125
- Monarch Platform$110
How this compares
$23,755 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 832 | $592,103 |
| OfevNintedanib Esylate | 21 | $274,259 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 146 | $91,720 |
| Breo ElliptaFluticasone/Vilanterol | 122 | $52,577 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 710 | $18,302 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $14,463 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $11,212 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $9,792 |
| Arnuity ElliptaFluticasone Furoate | 38 | $8,104 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,785 |
| Varenicline Tartrate | 30 | $7,345 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $7,002 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,897 |
| Spiriva HandihalerTiotropium Bromide | 12 | $5,862 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $3,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $904 | $670,9981,033 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat | $1,880 | $295,61963 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $632 | $101,513186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Calistoga
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Ken YonedaSacramento$173K
- Praveen AkuthotaSan Diego$169K
- Ivan ChengSan Francisco$162K
- Brian ShermanOxnard$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.